Friedreich's ataxia

Jump to navigation Jump to search
Friedreich's ataxia
ICD-10 G11.1
ICD-9 334.0
OMIM 229300
DiseasesDB 4980
MeSH D005621

WikiDoc Resources for Friedreich's ataxia

Articles

Most recent articles on Friedreich's ataxia

Most cited articles on Friedreich's ataxia

Review articles on Friedreich's ataxia

Articles on Friedreich's ataxia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Friedreich's ataxia

Images of Friedreich's ataxia

Photos of Friedreich's ataxia

Podcasts & MP3s on Friedreich's ataxia

Videos on Friedreich's ataxia

Evidence Based Medicine

Cochrane Collaboration on Friedreich's ataxia

Bandolier on Friedreich's ataxia

TRIP on Friedreich's ataxia

Clinical Trials

Ongoing Trials on Friedreich's ataxia at Clinical Trials.gov

Trial results on Friedreich's ataxia

Clinical Trials on Friedreich's ataxia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Friedreich's ataxia

NICE Guidance on Friedreich's ataxia

NHS PRODIGY Guidance

FDA on Friedreich's ataxia

CDC on Friedreich's ataxia

Books

Books on Friedreich's ataxia

News

Friedreich's ataxia in the news

Be alerted to news on Friedreich's ataxia

News trends on Friedreich's ataxia

Commentary

Blogs on Friedreich's ataxia

Definitions

Definitions of Friedreich's ataxia

Patient Resources / Community

Patient resources on Friedreich's ataxia

Discussion groups on Friedreich's ataxia

Patient Handouts on Friedreich's ataxia

Directions to Hospitals Treating Friedreich's ataxia

Risk calculators and risk factors for Friedreich's ataxia

Healthcare Provider Resources

Symptoms of Friedreich's ataxia

Causes & Risk Factors for Friedreich's ataxia

Diagnostic studies for Friedreich's ataxia

Treatment of Friedreich's ataxia

Continuing Medical Education (CME)

CME Programs on Friedreich's ataxia

International

Friedreich's ataxia en Espanol

Friedreich's ataxia en Francais

Business

Friedreich's ataxia in the Marketplace

Patents on Friedreich's ataxia

Experimental / Informatics

List of terms related to Friedreich's ataxia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]

Historical Perspective

Discovery

  • Friedreich’s ataxia was first discovered by Nikolaus Friedreich, a German pathologist and neurologist, in 1863.
  • The association between hereditary inheritance and Friedreich’s ataxia was made first time by Nikolaus Friedreich.
  • In 1996, the association between a GAA repeat expansion on chromosome 9 and the development of Friedreich's ataxia was discovered for the first time.

Famous Cases

  • Geraint Williams: He is known for scaling Mount Kilimanjaro in an adaptive wheelchair known as a Mountain Trike.

Classification

There is no established system for the classification of Friedreich's ataxia.

Pathophysiology

Pathogenesis and genetics

  • It is understood that Friedreich’s ataxia is the result of a homozygous guanine-adenine-adenine (GAA) trinucleotide repeat expansion on chromosome 9q13 that causes a transcriptional defect of the frataxin gene.
  • Frataxin is a small mitochondrial protein and deficiency of frataxin is responsible for all clinical and morphological manifestations of Friedreich’s ataxia.
  • The severity of the disease is directly related to the length of the trinucleotide repeat expansion and long expansions lead to early onset, severe clinical illness, and death in young adult life.
  • Patients with short trinucleotide repeat expansion have a later onset and a more benign course and even some of them are not diagnosed during life.
  • Friedreich’s ataxia is transmitted in autosomal recessive pattern.
  • Because the frataxin protein has multiple functions in the normal state, the exact role of frataxin deficiency in the pathogenesis of Friedreich's ataxia is still unclear. These functions include:
    • Biogenesis of iron-sulfur clusters
    • Iron chaperoning
    • Iron storage
    • Control of iron-mediated oxidative tissue damage

Associated Conditions

Conditions associated with friedreich’s ataxia include:

Gross Pathology

On gross pathology involvement of spinal cord, cerebellum, and heart are characteristic findings of Friedreich's ataxia.

Spinal cord lesions include:

Cerebellum lesions include:

Heart findings include:

Microscopic Pathology

On microscopic histopathological analysis, involvement of spinal cord, cerebellum, heart and pancreas are characteristic findings of Friedreich's ataxia.

Spinal cord

  • Friedreich’s ataxia mostly affects the dorsal root ganglia (DRG) of the spinal cord. It affects the entire DGR but is most prominent in subcapsular regions.
  • Cell stains in samples of DGN reveal:
    • An overall reduction in the size of ganglion cells
    • The absence of very large neurons and large myelinated fibers
    • Clusters of nuclei representing “residual nodules” that indicate an invasion-like entry of satellite cells into the cytoplasm of neurons.
    • Progressive destruction of neuronal cytoplasm in cytoskeletal stains, such as for class-III-β-tubulin
    • Greatly thickened satellite cells
    • Residual nodules remain strongly reactive with anti-S100α in the satellite cells
    • Increased ferritin immunoreactivity in satellite cells

Cerebellum

Heart

  • Cell stains in samples of heart reveal:[1]

Pancreas

Causes

Genetic Causes

Differentiating Friedreich’s ataxia from other Diseases

As Friedreich’s ataxia manifests in a variety of clinical forms and different ages, differentiation must be established in accordance with the manifestations of the disease and onset of the symptoms.

The main and most prominent symptom of the Friedreich’s ataxia is ataxia that worsens over time and it must be differentiated from other diseases that cause progressive ataxia such as:

Epidemiology and Demographics

Incidence

  • The incidence of Friedreich’s ataxia is approximately 2-4 per 100,000 individuals worldwide.

Prevalence

  • The prevalence of Friedreich’s ataxia is approximately 2-4 per 100,000 individuals worldwide.

Age

  • Friedreich ataxia commonly affects individuals from early childhood through to early adulthood, starting with poor balance when walking, followed by slurred speech and upper-limb ataxia.
  • Friedreich ataxia is usually first diagnosed at age 10 to 15 years but onset of disease may be as early as age 2 years and as late as the 8th decade.[2]

Race and Region

  • The GAA triplet repeat expansion that causes Friedreich ataxia usually affects only individuals of the European, North African, Middle Eastern, or Indian origin (Indo-European and Afro-Asiatic speakers).
  • Sub-Saharan Africans, Amerindians, and individuals from China, Japan, and Southeast Asia are less likely to develop Friedreich ataxia.

Gender

  • Friedreich ataxia affects men and women equally.[1]
  • Female are more commonly affected by clinical fractures than male.[2]

Risk Factors

  • Because Friedreich ataxia is a genetic diseases transmitted by autosomal recessive pattern, the most potent risk factor in the development of Friedreich ataxia is strong family history. Other risk factors are unknown.[3]
  • The risk factors for developing associated clinical conditions of Friedreich's ataxia include:[3]
    • GAA1 length
    • Age of diagnosis

Eponymjhjmfkkdiemmdkmvwkxmlkmwojdndkwqmas,ls,sckdlcm,sapl,as;ldpsclcmdl,a;,vndkm

It is named after the German physician Nicholaus Friedreich, who first described the condition in the 1860s.

Prevalence

Friedreich's ataxia, although rare, is the most prevalent inherited ataxia, affecting about 1 in 50,000 people in the United States. Males and females are affected equally.

Due to the relatively heterogenous population of Quebec, a 1984 Canadian study was able to trace 40 cases of classical Friedreich's disease from 14 previously unrelated French-Canadian kindreds to one common ancestral couple arriving in New France in 1634: Jean Guyon and Mathurine Robin.

Delatycki et al. (2000) provided an overview of the clinical features, pathology, molecular genetics, and possible therapeutic options in Friedreich ataxia.

Genetics

Friedreich's ataxia is an autosomal recessive congenital ataxia and is caused by a mutation in Gene X25 that codes for frataxin, located on chromosome 9. This protein is essential in neuronal and muscle cells for proper functioning mitochondria (it has been shown to be connected with the removal of iron from the cytoplasm surrounding the mitochondria, and in the absence of frataxin, the iron builds up and causes free radical damage).

The classic form has been mapped to 9q13-q21; the mutant gene contains expanded GAA triplet repeats in the first intron of "frataxin gene". Because the defect is located on an intron (which is removed from the mRNA transcript between transcription and translation), this mutation does not result in the production of abnormal frataxin proteins. Instead, the mutation causes gene silencing (the mutation decreases the transcription of the gene) through induction of a heterochromatin structure in a manner similar to position-effect variegation.

Relationship to muscular dystrophy

Friedreich's ataxia and muscular dystrophy, though often compared, are completely different diseases. Muscular dystrophy is the result of muscle tissue degeneration whereas Friedreich's ataxia is the result of nerve tissue degeneration caused by a trinucleotide repeat expansion mutation. Both are researched by the Muscular Dystrophy Association.

Types of Friedreich's ataxia

There are two types, the classic form and one in association with a genetic vitamin E deficiency. They cannot be distinguished clinically in lab.

Symptoms

Symptoms typically begin sometime between the ages of 5 to 15 years, but in Late Onset FA may occur in the 20's or 30's. Symptoms include any combination, but not necessarily all of the following:

  • Muscle weakness in the arms and legs
  • Loss of coordination
  • Vision impairment
  • Hearing loss
  • Slurred speech
  • Curvature of the spine (scoliosis)
  • High plantar arches
  • Diabetes
  • Extreme heart conditions (e.g., atrial fibrillation, and resultant tachycardia (fast heart rate) and cardiomyopathy (enlargement of the heart))

It presents before 25 years of age with progressive staggering gait, frequent falling and titubation. Lower extremities are more severely involved.

These symptoms are slow and progressive. Long-term observation shows that many patients reach a plateau in symptoms in the patient's early adulthood. Because of many of these symptoms, a person suffering from Friedrich's Ataxia may require some surgical interventions (mainly for the spine and heart). Often a metal rod is inserted in the spine to help prevent or slow the progression of scoliosis. As progression occurs, assistive devices such as a cane or walker or a wheelchair are required for mobility (independence).

Signs

  • Cerebellar: Nystagmus, fast saccadic eye movements, truncal titubation, dysarthria, dysmetria.
  • Pyramidal: absent deep tendon reflexes, extensor plantar responses, and distal weakness are commonly found.
  • Dorsal column: Loss of vibratory and proprioceptive sensation occurs.
  • Cardiac involvement occurs in 91% of patients, including cardiomegaly (up to dilated cardiomyopathy), symmetrical hypertrophy, murmurs, and conduction defects. Median age of death is 35 years, while females have better prognosis with a 20-year survival of 100% as compared to 63% in men.

20% cases are found in association with diabetes mellitus type 1 or 2 or pancreatic β cell dysfunction.

Diagnosis

  • Cardiac MRI is indicated in patients suspected of this disease.

AHA Scientific Statement: Management of Cardiac Involvement Associated With Neuromuscular Diseases

Cardiac Evaluation in Friedrich Ataxia (FA)

Class I
"1. Cardiology evaluation with examination, ECG, echocardiogram, and ambulatory electrocardiographic monitoring should occur at the time of FA diagnosis. (Level of Evidence: C) "
"2. Asymptomatic FA patients should be followed up at least annually with examination, ECG, and echocardiogram. (Level of Evidence: C) "
"3. Symptomatic FA patients should be followed up more frequently than annually. (Level of Evidence: C) "
Class IIa
"1. Ambulatory electrocardiographic monitor- ing or monitoring with an event recorder is reasonable in FA patients with symptoms of palpitations and in those without symptoms every 1 to 4 years, increasing in frequency with increasing age. (Level of Evidence: C) "

ACC/AHA Guidelines- ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance (DO NOT EDIT)

CMR may be used for assessment of patients with LV dysfunction or hypertrophy or suspected forms of cardiac injury not related to ischemic heart disease. When the diagnosis is unclear, CMR may be considered to identify the etiology of cardiac dysfunction in patients presenting with heart failure, including

  • evaluation of dilated cardiomyopathy in the setting of normal coronary arteries,
  • patients with positive cardiac enzymes without obstructive atherosclerosis on angiography,
  • patients suspected of amyloidosis or other infiltrative diseases,
  • hypertrophic cardiomyopathy,
  • arrhythmogenic right ventricular dysplasia, or
  • syncope or ventricular arrhythmia.

Pathogenesis

The primary site of pathology is spinal cord and peripheral nerves. Sclerosis and degeneration of spinocerebellar tracts, lateral corticospinal tracts, and posterior columns. In peripheral nerves there is a loss of large myelinated fibres.

Treatment

The symptoms can be treated but there is no treatment for Friedrich's Ataxia at this time. There are several clinical trials taking place, including one for idebenone, in the United States. Assistive Technology, such as a standing frame, can help reduce the secondary complications of prolonged use of a wheelchair. In many cases, patients experience significant heart conditions as well. These conditions, fortunately, are much more treatable, and are often countered with ACE inhibitors such as Lisinopril and other heart medications such as Digoxin.

Current Research

Recent research led by Joel Gottesfeld of The Scripps Research Institute has indicated that Histone Deacetylase Inhibitors are able to reverse the silencing of the frataxin gene in human primary lymphocytes. This class of chemicals is thought to enable DNA transcription of the frataxin gene because the inhibition of histone deacetylation, makes the terminal tails of histones H3 and H4 more likely to remain fully acetylated. Acetylation removes the positive charge from the lysine (an amino acid that is a part of the n-terminal tail of the histone proteins), and thus makes the histones less able to neutralize the charges of the DNA (specifically the negatively charged phosphate backbone). This causes the DNA and the histone proteins to be less condensed (back to the form of euchromatin). This increases the ability of regulatory proteins and RNA polymerases to access the frataxin gene, and therefore returns the transcription (and the overall expression) of the frataxin gene to normal levels.

Because the genetic defect occurs in the intron, the excess nucleotides repeats are removed from the mRNA transcript, and the resulting frataxin proteins are not defective. The HDACi chemicals effect the histone proteins throughout the cell, but gene expression microarray experiments reveal that the effects are limited, and do not appear to be clustered into any family of genes that might cause deleterious side effects. The compounds are not cytotoxic to lymphocytes or to mice when administered at therapeutic doses.

On April 11th, 2007, Repligen Corporation, a biopharmaceutical company, entered into an exclusive commercial license with The Scripps Research Institute for the development of HDACi compounds that could have clinical uses in the treatment of Friedreich's Ataxia.

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Marcus AJ, Safier LB, Ullman HL, Islam N, Broekman MJ, Falck JR, Fischer S, von Schacky C (1988). "Cell-cell interactions in the eicosanoid pathways". Prog. Clin. Biol. Res. 283: 559–67. PMID 3062632.
  2. 2.0 2.1 Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean L, Stephens K, Amemiya A, Bidichandani SI, Delatycki MB. PMID 20301458. Vancouver style error: initials (help); Missing or empty |title= (help)
  3. 3.0 3.1 Lazo JS, Hait WN, Kennedy KA, Braun ID, Meandzija B (March 1985). "Enhanced bleomycin-induced DNA damage and cytotoxicity with calmodulin antagonists". Mol. Pharmacol. 27 (3): 387–93. PMID 2579318.

External links

Friedreich's Ataxia Research Alliance (FARA) http://www.cureFA.org

Patient Recruitment for Friedreich's Ataxia Upcoming Clinical Research Trials: to sign up http://www.cureFA.org/registry/

FARA Electronic News Bulletin for latest research and news relevant to Friedreich's ataxia: To sign up http://visitor.constantcontact.com/email.jsp?m=1101190303489

Template:Diseases of the nervous system Template:Mitochondrial diseases

ca:Atàxia de Friedreich de:Friedreich-Ataxie he:אטקסיית פרידרייך hu:Friedreich ataxia

Template:Jb1

Template:WikiDoc Sources